User:Jacob Holt/Sandbox 1
From Proteopedia
(Difference between revisions)
| Line 9: | Line 9: | ||
The primary job of SCD1 in the body is to catalyze the biosynthesis of monounsaturated fatty acids (MUFAs) via saturated [https://en.wikipedia.org/wiki/Acyl-CoA Acyl-CoAs] with an acyl chain length of 14-19 carbons<ref name="Paton" /><ref name="Shen" />. Variations of the monounsaturated fatty acids function as precursors for the biosynthesis of [https://en.wikipedia.org/wiki/Phospholipid phospholipids], cholesterol esters, and triglycerides; therefore, SCD1 is a promising candidate for drug targeting1. Absence or a deficit of SCD1 in the body is associated with obesity and insulin resistance which is a main cause of [https://en.wikipedia.org/wiki/Type_2_diabetes type II diabetes]<ref name="Shen" />. Cancer sites in the body tend to show a much higher expression rate of SCD13. Focusing on SCD1 as a drug target could lead to advancements in treatment of obesity, diabetes, and other metabolic diseases<ref name="Bai" />. | The primary job of SCD1 in the body is to catalyze the biosynthesis of monounsaturated fatty acids (MUFAs) via saturated [https://en.wikipedia.org/wiki/Acyl-CoA Acyl-CoAs] with an acyl chain length of 14-19 carbons<ref name="Paton" /><ref name="Shen" />. Variations of the monounsaturated fatty acids function as precursors for the biosynthesis of [https://en.wikipedia.org/wiki/Phospholipid phospholipids], cholesterol esters, and triglycerides; therefore, SCD1 is a promising candidate for drug targeting1. Absence or a deficit of SCD1 in the body is associated with obesity and insulin resistance which is a main cause of [https://en.wikipedia.org/wiki/Type_2_diabetes type II diabetes]<ref name="Shen" />. Cancer sites in the body tend to show a much higher expression rate of SCD13. Focusing on SCD1 as a drug target could lead to advancements in treatment of obesity, diabetes, and other metabolic diseases<ref name="Bai" />. | ||
| - | |||
| - | <scene name='87/877552/Diiron_center/5'>Diiron center</scene> | ||
| Line 33: | Line 31: | ||
== Structural highlights == | == Structural highlights == | ||
| + | |||
| + | <scene name='87/878231/Active_site_cap/1'>Gly 287 and Tyr 104 capping off the active site</scene> | ||
| + | |||
| + | |||
| + | <scene name='87/877552/Diiron_center/5'>Diiron center</scene> | ||
| + | |||
[[Image:SCD1_New.jpeg|500px|Right|]] | [[Image:SCD1_New.jpeg|500px|Right|]] | ||
Revision as of 14:40, 30 March 2021
Mouse Stearoyl-CoA Desaturase-1 Structure
| |||||||||||
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Bai Y, McCoy JG, Levin EJ, Sobrado P, Rajashankar KR, Fox BG, Zhou M. X-ray structure of a mammalian stearoyl-CoA desaturase. Nature. 2015 Jun 22. doi: 10.1038/nature14549. PMID:26098370 doi:http://dx.doi.org/10.1038/nature14549
- ↑ 2.0 2.1 Paton CM, Ntambi JM. Biochemical and physiological function of stearoyl-CoA desaturase. Am J Physiol Endocrinol Metab. 2009 Jul;297(1):E28-37. doi:, 10.1152/ajpendo.90897.2008. Epub 2008 Dec 9. PMID:19066317 doi:http://dx.doi.org/10.1152/ajpendo.90897.2008
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Shen J, Wu G, Tsai AL, Zhou M. Structure and Mechanism of a Unique Diiron Center in Mammalian Stearoyl-CoA Desaturase. J Mol Biol. 2020 May 27. pii: S0022-2836(20)30367-3. doi:, 10.1016/j.jmb.2020.05.017. PMID:32470559 doi:http://dx.doi.org/10.1016/j.jmb.2020.05.017
Student Contributions
Delete Later:
